Orlistat Market Report 2026

The orlistat market size has grown strongly in recent years. It will grow from $3.2 billion in 2025 to $3.4 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising prevalence of obesity and overweight population, increasing clinical acceptance of orlistat, growing availability of otc orlistat, rising health awareness campaigns on obesity, early adoption of orlistat in developed markets.

The orlistat market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to expanding adoption of orlistat in emerging markets, growing preference for non-invasive obesity treatments, increasing integration of orlistat in weight management programs, rising healthcare initiatives for obesity prevention, technological advancements in formulation and delivery methods. Major trends in the forecast period include rising adoption of orlistat as a weight management therapy, increasing preference for prescription and otc orlistat formulations, growing focus on combining orlistat with lifestyle interventions, rising demand for low-fat diet-compatible weight loss solutions, increasing awareness about obesity management and preventive care.

The rising prevalence of obesity is expected to drive the growth of the orlistat market in the coming years. Obesity is a medical condition marked by excessive accumulation of body fat, which adversely affects overall health, typically defined by a body mass index (BMI) of 30 or higher. The increase in obesity is linked to poor dietary habits, sedentary lifestyles, and lack of physical activity. Orlistat aids in obesity management by inhibiting the absorption of dietary fats, helping reduce body weight and maintain long-term weight loss. It is generally prescribed alongside a reduced-calorie diet and regular exercise for optimal results. For example, in 2024, the World Obesity Federation, a UK-based non-profit organization, reported that by 2035, 79% of adults with overweight and obesity and 88% of children with overweight and obesity will reside in Low- and Middle-Income Countries (LMICs). Therefore, the rising obesity rates are fueling the growth of the orlistat market.

Companies in the orlistat market are focusing on innovations in weight loss drugs to improve patient outcomes and convenience through advanced technology and therapeutic mechanisms. Weight loss drugs are medications designed to help individuals reduce body weight by suppressing appetite, enhancing metabolism, or blocking fat absorption. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical firm, received FDA approval for Zepbound (tirzepatide) injection, a novel weight loss medication. It is the first approved treatment to activate both GIP and GLP-1 incretin hormone receptors, addressing an underlying cause of excess weight. Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related condition.

In August 2023, Eli Lilly and Company acquired Versanis Bio for $1.93 billion to expand its portfolio in weight management. This acquisition incorporates Versanis’ lead asset, bimagrumab, which is under evaluation in a Phase 2b study both as a standalone therapy and in combination with semaglutide for adults with overweight or obesity. Versanis Bio Inc., a US-based biotech company, develops medicines targeting overweight and obese adults to address medical conditions related to excess weight.

Major companies operating in the orlistat market are Merck & Co. Inc., GlaxoSmithKline plc, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr Reddys Laboratories Ltd., Cipla Ltd., Intas Pharmaceuticals Ltd., Lupin Pharmaceuticals Inc., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Zydus Life, Emcure Pharmaceuticals Ltd., Lannett Company Inc., Strides Pharma Science Ltd., Indoco Remedies Ltd., Wockhardt Ltd., Jubilant Life Sciences Ltd., Aurobindo Pharma Ltd.

North America was the largest region in the orlistat market in 2025. The regions covered in the orlistat market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the orlistat market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the orlistat market by increasing costs for imported active pharmaceutical ingredients, excipients, and specialized packaging required for both prescription and otc formulations. These effects are most visible in north america, europe, and asia-pacific, affecting hospital and retail pharmacy distribution segments. Tariffs have led to higher production costs and delays in supply chains. However, they have also encouraged local sourcing, domestic production of key components, and improved regional supply chain resilience.

The orlistat market research report is one of a series of new reports that provides orlistat market statistics, including orlistat industry global market size, regional shares, competitors with a orlistat market share, detailed orlistat market segments, market trends and opportunities, and any further data you may need to thrive in the orlistat industry. This orlistat market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Orlistat is a medication that supports weight loss by blocking the absorption of dietary fats, thereby reducing calorie intake. It works by inhibiting the enzyme lipase, which is essential for breaking down fats in the intestine. Orlistat is typically prescribed for individuals who are overweight or obese and is most effective when combined with a low-fat diet and regular exercise.

The main types of orlistat are 120 milligrams (mg) and 60 milligrams (mg). The 120 mg dosage is commonly used to help obese patients lose weight by preventing fat absorption and is usually taken three times a day with meals containing fat. Orlistat is distributed through hospital pharmacies, online pharmacies, and retail pharmacies, and is used for applications such as weight reduction and related purposes.

The orlistat market consists of sales of xenical, combination supplements, and dietary aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.